Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections

{ 'indexed': {'date-parts': [[2023, 6, 2]], 'date-time': '2023-06-02T04:26:10Z', 'timestamp': 1685679970557}, 'reference-count': 20, 'publisher': 'MDPI AG', 'issue': '6', 'license': [ { 'start': { 'date-parts': [[2023, 5, 31]], 'date-time': '2023-05-31T00:00:00Z', 'timestamp': 1685491200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>Sotrovimab, an antibody active against severe acute respiratory syndrome coronavirus ' '2 that neutralizes antibodies, reduced the risk of COVID-19-related hospitalization or death ' 'in studies conducted before the emergence of the Omicron variant. The objective of this study ' 'is to evaluate the clinical efficacy of sotrovimab in patients with mild to moderate COVID-19 ' 'Omicron BA.1 and BA.2 subvariant infections using a propensity score matching method. The ' 'propensity score-matched cohort study population was derived from patients who received ' 'sotrovimab. We derived a comparator group from an age- and sex-matched population who were ' 'recuperating in a medical facility after COVID-19 infection or from elderly person entrance ' 'facilities during the same period who were eligible for but did not receive sotrovimab ' 'treatment. In total, 642 patients in the BA.1 subvariant group and 202 in the BA.2 subvariant ' 'group and matched individuals were analyzed. The outcome was the requirement for oxygen ' 'therapy. In the treatment group, 26 patients with the BA.1 subvariant and 8 patients with the ' 'BA.2 subvariant received oxygen therapy. The administration of oxygen therapy was ' 'significantly lower in the treatment group than in the control group (BA.1 subvariant group, ' '4.0% vs. 8.7%, p = 0.0008; BA.2 subvariant group, 4.0% vs. 9.9%, p = 0.0296). All these ' 'patients were admitted to our hospitals and received additional therapy and then recovered. ' 'No deaths were observed in either group. Our results demonstrate that the sotrovimab antibody ' 'treatment may be associated with a reduction in the requirement for oxygen therapy among ' 'high-risk patients with mild to moderate COVID-19 Omicron BA.1 and BA.2 subvariants.</jats:p>', 'DOI': '10.3390/v15061300', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T05:40:56Z', 'timestamp': 1685598056000}, 'page': '1300', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 ' 'Omicron BA.1 and BA.2 Subvariant Infections', 'prefix': '10.3390', 'volume': '15', 'author': [ { 'given': 'Naoyuki', 'family': 'Miyashita', 'sequence': 'first', 'affiliation': [ { 'name': 'Division of Respiratory Medicine, Infectious Disease and ' 'Allergology, First Department of Internal Medicine, Kansai ' 'Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, ' 'Japan'}]}, { 'given': 'Yasushi', 'family': 'Nakamori', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Emergency Medicine, Kansai Medical University ' 'Medical Center, Moriguchi 570-8507, Japan'}]}, { 'given': 'Makoto', 'family': 'Ogata', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Respiratory Medicine, Infectious Disease and ' 'Allergology, First Department of Internal Medicine, Kansai ' 'Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, ' 'Japan'}]}, { 'given': 'Naoki', 'family': 'Fukuda', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Respiratory Medicine, Infectious Disease and ' 'Allergology, First Department of Internal Medicine, Kansai ' 'Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, ' 'Japan'}]}, { 'given': 'Akihisa', 'family': 'Yamura', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Respiratory Medicine, Infectious Disease and ' 'Allergology, First Department of Internal Medicine, Kansai ' 'Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, ' 'Japan'}]}, { 'given': 'Yoshihisa', 'family': 'Ishiura', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Respiratory Medicine, Oncology and Allergology, ' 'First Department of Internal Medicine, Kansai Medical University ' 'Medical Center, Moriguchi 570-8507, Japan'}]}, { 'given': 'Tomoki', 'family': 'Ito', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Respiratory Medicine, Infectious Disease and ' 'Allergology, First Department of Internal Medicine, Kansai ' 'Medical University, 2-3-1 Shin-machi, Hirakata 573-1191, ' 'Japan'}]}], 'member': '1968', 'published-online': {'date-parts': [[2023, 5, 31]]}, 'reference': [ { 'key': 'ref_1', 'doi-asserted-by': 'crossref', 'first-page': '1941', 'DOI': '10.1056/NEJMoa2107934', 'article-title': 'COMET-ICE Investigators. Early Treatment for COVID-19 with SARS-CoV-2 ' 'Neutralizing Antibody Sotrovimab', 'volume': '385', 'author': 'Gupta', 'year': '2021', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref_2', 'doi-asserted-by': 'crossref', 'first-page': '1236', 'DOI': '10.1001/jama.2022.2832', 'article-title': 'COMET-ICE Investigators. Effect of sotrovimab on hospitalization or ' 'death among high-risk patients with mild to moderate COVID-19: A ' 'randomized clinical trial', 'volume': '327', 'author': 'Gupta', 'year': '2022', 'journal-title': 'JAMA'}, { 'key': 'ref_3', 'doi-asserted-by': 'crossref', 'first-page': 'e2220957', 'DOI': '10.1001/jamanetworkopen.2022.20957', 'article-title': 'Effectiveness of casirivimab-imdevimab and sotrovimab during a ' 'SARS-CoV-2 Delta variant surge. A cohort study and randomized ' 'comparative effectiveness trial', 'volume': '5', 'author': 'Huang', 'year': '2022', 'journal-title': 'JAMA Netw. Open'}, { 'key': 'ref_4', 'doi-asserted-by': 'crossref', 'first-page': '2129', 'DOI': '10.1093/infdis/jiac206', 'article-title': 'Real-world evidence of the neutralizing monoclonal antibody sotrovimab ' 'for preventing hospitalization and mortality in COVID-19 outpatients', 'volume': '226', 'author': 'Aggarwal', 'year': '2022', 'journal-title': 'J. Infect. Dis.'}, { 'key': 'ref_5', 'doi-asserted-by': 'crossref', 'unstructured': 'Ong, S.W.X., Ren, D., Lee, P.H., Sutjipto, S., Dugan, C., Khoo, B.Y., ' 'Tay, J.X., Vasoo, S., Young, B.E., and Lyeet, D.C. (2022). Real-world ' 'use of sotrovimab for pre-emptive treatment in high-risk hospitalized ' 'COVID-19 patients: An observational cross-sectional study. Antibiotics, ' '11.', 'DOI': '10.3390/antibiotics11030345'}, { 'key': 'ref_6', 'doi-asserted-by': 'crossref', 'first-page': '995', 'DOI': '10.1056/NEJMc2119407', 'article-title': 'Efficacy of antibodies and antiviral drugs against COVID-19 omicron ' 'variant', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref_7', 'doi-asserted-by': 'crossref', 'first-page': '1252', 'DOI': '10.1038/s41564-022-01170-4', 'article-title': 'Therapeutic efficacy of monoclonal antibodies and antivirals against ' 'SARS-CoV-2 Omicron BA.1 in Syrian hamsters', 'volume': '7', 'author': 'Uraki', 'year': '2022', 'journal-title': 'Nature Microbiol.'}, { 'key': 'ref_8', 'doi-asserted-by': 'crossref', 'first-page': '1475', 'DOI': '10.1056/NEJMc2201933', 'article-title': 'Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant ' 'BA.2', 'volume': '386', 'author': 'Takashita', 'year': '2022', 'journal-title': 'N. Engl. J. Med.'}, { 'key': 'ref_9', 'doi-asserted-by': 'crossref', 'first-page': '553', 'DOI': '10.1038/s41586-022-04594-4', 'article-title': 'Antibody evasion properties of SARS-CoV-2 Omicron sublineages', 'volume': '604', 'author': 'Iketani', 'year': '2022', 'journal-title': 'Nature'}, { 'key': 'ref_10', 'doi-asserted-by': 'crossref', 'unstructured': 'Cathcart, A.L., Havenar-Daughton, C., Lempp, F.A., Ma, D., Schmid, M.A., ' 'Agostini, M.L., Guarino, B., Di Iulio, J., Rosen, L.E., and Tucker, H. ' '(2022). The dual function monoclonal antibodies VIR-7831 and VIR-7832 ' 'demonstrate potent in vitro and in vivo activity against SARS-CoV-2 ' '(version 12). bioRxiv.', 'DOI': '10.1101/2021.03.09.434607'}, { 'key': 'ref_11', 'doi-asserted-by': 'crossref', 'unstructured': 'Park, Y.J., Pinto, D., Walls, A.C., Liu, Z., De Marco, A., Benigni, F., ' 'Zatta, F., Silacci-Fregni, C., Bassi, J., and Sprouse, K.R. (2022). ' 'Imprinted antibody responses against SARS-CoV-2 Omicron sublineages ' '(version 4). bioRxiv.', 'DOI': '10.1101/2022.05.08.491108'}, { 'key': 'ref_12', 'doi-asserted-by': 'crossref', 'first-page': '3824', 'DOI': '10.1038/s41467-022-31615-7', 'article-title': 'Resilience of S309 and AZD7442 monoclonal antibody treatments against ' 'infection by SARS-CoV-2 Omicron lineage strains', 'volume': '13', 'author': 'Case', 'year': '2022', 'journal-title': 'Nat. Commun.'}, { 'key': 'ref_13', 'doi-asserted-by': 'crossref', 'first-page': '100850', 'DOI': '10.1016/j.xcrm.2022.100850', 'article-title': 'Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron ' 'BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies', 'volume': '3', 'author': 'Bruel', 'year': '2022', 'journal-title': 'Cell Rep. Med.'}, { 'key': 'ref_14', 'doi-asserted-by': 'crossref', 'first-page': '2010', 'DOI': '10.1515/cclm-2021-0700', 'article-title': 'Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine', 'volume': '59', 'author': 'Meschi', 'year': '2021', 'journal-title': 'Clin. Chem. Lab. Med.'}, { 'key': 'ref_15', 'unstructured': 'ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group ' '(2022). Efficacy and safety of two neutralising monoclonal antibody ' 'therapies, sotrovimab and BRII-196 plus BRII-198, for adults ' 'hospitalised with COVID-19 (TICO): A randomised controlled trial. Lancet ' 'Infect. Dis., 22, 622–635.'}, { 'key': 'ref_16', 'doi-asserted-by': 'crossref', 'first-page': '607', 'DOI': '10.1007/s40121-022-00755-0', 'article-title': 'Real-world effectiveness of sotrovimab for the early treatment of ' 'COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA', 'volume': '12', 'author': 'Cheng', 'year': '2023', 'journal-title': 'Infect. Dis. Ther.'}, { 'key': 'ref_17', 'doi-asserted-by': 'crossref', 'first-page': 'e071932', 'DOI': '10.1136/bmj-2022-071932', 'article-title': 'Comparative effectiveness of sotrovimab and molnupiravir for prevention ' 'of severe COVID-19 outcomes in patients in the community: Observational ' 'cohort study with the OpenSAFELY platform', 'volume': '379', 'author': 'Zheng', 'year': '2022', 'journal-title': 'BMJ'}, { 'key': 'ref_18', 'doi-asserted-by': 'crossref', 'first-page': 'e104', 'DOI': '10.1016/j.jinf.2022.06.033', 'article-title': 'Sotrovimab to prevent severe COVID-19 in high-risk patients infected ' 'with Omicron BA.2', 'volume': '85', 'author': 'Marcelin', 'year': '2022', 'journal-title': 'J. Infect.'}, { 'key': 'ref_19', 'doi-asserted-by': 'crossref', 'first-page': '96', 'DOI': '10.1016/j.ijid.2022.09.023', 'article-title': 'Effectiveness of the neutralizing antibody sotrovimab among high-risk ' 'patients with mild-to-moderate SARS-CoV-2 in Qatar', 'volume': '124', 'author': 'Zaqout', 'year': '2022', 'journal-title': 'Int. J. Infect. Dis.'}, { 'key': 'ref_20', 'doi-asserted-by': 'crossref', 'unstructured': 'Addetia, A., Piccoli, L., Case, J.B., Park, Y.J., Beltramello, M., ' 'Guarino, B., Dang, H., Pinto, D., Scheaffer, S.M., and Sprouse, K. ' '(2023). Therapeutic and vaccine-induced cross-reactive antibodies with ' 'effector function against emerging Omicron variants (version 2). ' 'bioRxiv.', 'DOI': '10.1101/2023.01.17.523798'}], 'container-title': 'Viruses', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.mdpi.com/1999-4915/15/6/1300/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T05:43:51Z', 'timestamp': 1685598231000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.mdpi.com/1999-4915/15/6/1300'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 5, 31]]}, 'references-count': 20, 'journal-issue': {'issue': '6', 'published-online': {'date-parts': [[2023, 6]]}}, 'alternative-id': ['v15061300'], 'URL': 'http://dx.doi.org/10.3390/v15061300', 'relation': {}, 'ISSN': ['1999-4915'], 'subject': ['Virology', 'Infectious Diseases'], 'container-title-short': 'Viruses', 'published': {'date-parts': [[2023, 5, 31]]}}